Translational Tumor Immunology

Wistar's Translational Tumor Immunology (TTI) program is focused on the investigation of the mechanisms regulating immune responses in cancer and their potential therapeutic manipulation. Members of the program study the role of myeloid cells (dendritic cells, macrophages, neutrophils and myeloid-derived suppressor cells), regulatory T cells, and B cells in immune responses in cancer and infectious diseases. They study mechanisms responsible for the function of these cells using state-of-the-art genetic and molecular biology tools. 

A large part of these research activities is focused on a translational effort. Using experimental animal models and tissues obtained from cancer patients, members of the program are developing new approaches to therapeutic regulation of the immune system and tumor microenvironment. One of the important features of the program is an emphasis on collaboration with investigators from other programs at The Wistar Institute, as well as the University of Pennsylvania and several pharmaceutical companies. 


Members:

Dmitry Gabrilovich, M.D., Ph.D., Program Leader
Andrew Caton, Ph.D.
Jan Erikson, Ph.D.
Andrew Hu, Ph.D.
Luis Montaner, D.V.M., D.Phil.
Erica Stone, Ph.D.